

Randomized controlled trials reporting clinical endpoints for VOC

Isabelle Boutron

*Research Center of Epidemiology and Statistics (CRESS-U1153)
Université de Paris, Inserm, France*

*WHO consultation on COVID-19 vaccines research
3 September 2021*

COVID-NMA living systematic review




- COVID-NMA living systematic review
 - Complex process with daily searches to identify Randomized Controlled Trials assessing COVID-19 vaccines
 - All data are made available online (covid-nma.com)
- September 2021
 - 323 registered RCTs assessing vaccine for COVID-19 (131 recruiting)
 - 60 RCTs published
 - 7 RCTs reporting data on variants of concern (VOC)

Results available online

<https://covid-nma.com>


RCT evidence on variants of concern - Alpha

Symptomatic Confirmed COVID-19



RCT evidence on variants of concern - Beta

Symptomatic Confirmed COVID-19




RCT evidence on variants of concern - Delta

Double blind RCT
25 hospitals in India

Symptomatic Confirmed COVID-19

Type of variant: Delta (B.1.617.2)



Conclusions

- Limited evidence from RCTs on vaccine effectiveness on variants of concern
- Methodological issues
 - Post-hoc analyses
 - Lack of power
 - Missing outcome data
 - Heterogenous measurements of outcome (indirect evidence)
- Data from observational studies will provide additional information